Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans

Acta Ophthalmologica

Volumn 90, Issue 1, 2012, Pages 68-70

  Meyer, Carsten H ^a   Krohne, Tim U ^a,b   Holz, Frank G ^a  

^a UNIVERSITY OF BONN   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

fellow eye; intravitreal injection; unbound bevacizumab

Indexed keywords

BEVACIZUMAB;

AQUEOUS HUMOR; ARTICLE; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIMIT OF DETECTION; PHACOEMULSIFICATION; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMANS; INTRAVITREAL INJECTIONS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958759283     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01842.x     Document Type: Article

References (16)

1. Al-Dhibi H, &, Khan AO, (2009): Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 13: 400-402.
2. Avery RL, Pearlman J, Pieramici D, et al., (2006): Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695-1705.
3. Bakri SJ, Snyder MR, Reid JM, Pulido JS, &, Singh RJ, (2007): Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855-859. (Pubitemid 46635858)
4. Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, &, Arron JR, (2009): Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 116: 2158-2164.
5. Carneiro A, Falcão M, Azevedo I, Falcão Reis F, &, Soares R, (2008): Multiple effects of bevacizumab in angiogenesis: implications for its use in age-related macular degeneration. Acta Ophthalmol 87: 517-523.
6. Krohne TU, Eter N, Holz FG, &, Meyer CH, (2008): Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146: 508-512.
7. Mennel S, Callizo J, Schmidt JC, &, Meyer CH, (2007): Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 85: 689-691. (Pubitemid 47316777)
8. Neri P, Mariotti C, Mercanti L, Salvolini S, &, Giovannini A, (2008): Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 28: 425-427.
9. Nomoto H, Shiraga F, Kuno N, et al., (2009): Pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50: 4807-4813. (Accepted).
10. Sawada O, Kawamura H, Kakinoki M, &, Ohji M, (2008): Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 246: 1379-1381.
11. Shima C, Sakaguchi H, Gomi F, et al., (2008): Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86: 372-376.
12. Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers MB III, Morales-Catõn V, &, Quiroz-Mercado H, (2009): The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 29: 20-26.
13. Wang Y, Fei D, Vanderlaan M, &, Song A, (2004): Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7: 335-345. (Pubitemid 40767935)
14. Wu Z, &, Sadda SR, (2008): Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 37: 591-593.
15. Yoon YH, Kim JG, Chung H, &, Lee SY, (2009): Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. Acta Ophthalmol 87: 685-687.
16. Ziemssen F, Zhu Q, Peters S, et al., (2009). Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 29: 213-224.